caa a22 4500 477056253 CHVBK 20180405111347.0 cr unu---uuuuu 170330e19961201xx s 000 0 eng 10.1007/s002280050194 doi (NATIONALLICENCE)springer-10.1007/s002280050194 Haemodynamic effects and pharmacokinetics of oral d-and l-nebivolol in hypertensive patients [Elektronische Daten] [A. Himmelmann, T. Hedner, E. Snoeck, B. Lundgren, J. Hedner] Objective: Nebivolol is a selective β1-adrenergic receptor blocker possessing an ancillary vasodilating effect. The objective of the present study was to study the haemodynamic and pharmacokinetic properties of nebivolol 5 mg once daily in a double-blind, placebo-controlled cross-over study. Methods: Fifteen patients, 12 men and 3 women, with essential hypertension were investigated. Blood pressure and peripheral circulation were determined after acute oral nebivolol administration, 5 mg daily, and after 4 weeks treatment. Results: The acute effect on blood pressure upon single-dosing was weak and non-significant. After 4 weeks both systolic blood pressure (152 vs 163 mmHg) and diastolic blood pressure (89 vs 97 mmHg) were significantly reduced after nebivolol treatment as compared to placebo. Following the first dose the venous volume was higher on placebo (5.88 ml ⋅ 100 ml−1 tissue) as compared to active nebivolol treatment (5.17 ml ⋅ 100 ml−1 tissue), while there were no statistically significant differences with regard to venous plethysmographic findings after 1 month on placebo (5.53 ml ⋅ 100 ml−1 tissue) or on active treatment (5.97 ml ⋅ 100 ml−1 tissue). Calculated peripheral resistance did not differ between active treatment (617 units) or placebo (548 units) after the first dose, whereas it was significantly lowered after 4 weeks of nebivolol treatment (483 units) as compared to placebo (593 units). Conclusions: Oral nebivolol 5 mg once daily lowered blood pressure and heart rate during steady state compared to placebo. Moreover, venous volume was reduced during acute but not steady-state dosing, while peripheral resistance was unaffected in the acute phase but reduced during steady state. Plasma concentrations of the separate enantiomers plus hydroxylated metabolites after the first and last dose in hypertensive patients were similar to those in healthy subjects. Springer-Verlag Berlin Heidelberg, 1996 Key words Nebivolol nationallicence Hypertension nationallicence d nationallicence l-enantiomers nationallicence pharmacokinetics nationallicence man nationallicence Himmelmann A. Department of Clinical Pharmacology, Sahlgrenska University Hospital, 5-41345 Göteborg, Sweden, SE aut Hedner T. Department of Clinical Pharmacology, Sahlgrenska University Hospital, 5-41345 Göteborg, Sweden, SE aut Snoeck E. Janssen Pharma, Västra Frölunda, Sweden and Janssen Research, Beerse, Belgium, BE aut Lundgren B. Janssen Pharma, Västra Frölunda, Sweden and Janssen Research, Beerse, Belgium, BE aut Hedner J. Department of Clinical Pharmacology, Sahlgrenska University Hospital, 5-41345 Göteborg, Sweden, SE aut https://doi.org/10.1007/s002280050194 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s002280050194 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Himmelmann A. Department of Clinical Pharmacology, Sahlgrenska University Hospital, 5-41345 Göteborg, Sweden, SE aut NATIONALLICENCE 700 1- Hedner T. Department of Clinical Pharmacology, Sahlgrenska University Hospital, 5-41345 Göteborg, Sweden, SE aut NATIONALLICENCE 700 1- Snoeck E. Janssen Pharma, Västra Frölunda, Sweden and Janssen Research, Beerse, Belgium, BE aut NATIONALLICENCE 700 1- Lundgren B. Janssen Pharma, Västra Frölunda, Sweden and Janssen Research, Beerse, Belgium, BE aut NATIONALLICENCE 700 1- Hedner J. Department of Clinical Pharmacology, Sahlgrenska University Hospital, 5-41345 Göteborg, Sweden, SE aut Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer